E-Mail
Research by Australian scientists could pave the way to a new treatment for a currently incurable brain cancer in children called Diffuse Intrinsic Pontine Glioma, or DIPG. Affecting about 20 children in Australia each year, DIPG is a devastating disease with an average survival time of just nine months after diagnosis.
The research, led by scientists at Children s Cancer Institute and published this week in the international journal,
Cell Reports, offers an exciting new therapeutic approach for the treatment of DIPG by using a new anti-cancer drug.
The new drug, CBL0137, is an anti-cancer compound developed from the antimalarial drug quinacrine. The researchers found that CBL0137 directly reverses the effects of the key genetic drivers in DIPG, and has a profound effect against DIPG tumour models. They also foundCBL0137 is even more effective when combined with a second drug, panobinostat, a new type of drug known as a histone deacetylase (HDAC) inhibitor. When used
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Campaign Monitor Announces Salesforce CRM Integration Built by Beaufort 12 Limited
Campaign MonitorApril 11, 2021 GMT
NASHVILLE, Tenn., April 11, 2021 (GLOBE NEWSWIRE) Campaign Monitor, a CM Group brand and provider of powerful yet intuitive email marketing software, today announced a Salesforce CRM integration. The Campaign Monitor for Salesforce app, the top-rated email service provider app for Salesforce, is built with customer support and easy integration in mind. Available on the AppExchange, Campaign Monitor customers can now access all of their Salesforce data, create dashboards and easily trigger transactional emails within minutes and without ever leaving the platform.
Campaign Monitor Announces Salesforce CRM Integration Built by Beaufort 12 Limited globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Scalability and automation for their ever-growing volume of emails and subscribers
“With the platform we were using before, everything was very manual,” said Alex Dobbing, Director of Fundraising and Development. “There was no sort of triggered automation to get our subscribers to keep engaging. We wanted to get more clever and make the most of building up our community.”
With a new more powerful tool, the nonprofit was able to increase the frequency, precision and relevance of its email campaigns including the Walk4BrainCancer event. And more automated customer journeys and triggered emails meant messaging was more personal and got sent right at the most opportune time to get subscribers to act.
Researchers find potential new treatment for fatal childhood brain cancer ANI | Updated: Feb 14, 2021 19:22 IST
Washington [US], February 14 (ANI): Every year around 20 Australian children die from the incurable brain tumour, Diffuse Intrinsic Pontine Glioma (DIPG). The average age of diagnosis for DIPG is just seven years. There are no effective treatments, and almost all children die from the disease, usually within one year of diagnosis.
A paper published in the journal Nature Communications, reveals a potential revolutionary drug combination that in animal studies and in world-first 3D models of the tumour is spectacularly effective in eradicating the cancer cells, according to lead researcher and paediatric oncologist Associate Professor c from the Children s Cancer Institute and Sydney Children s Hospital.